Pricing analysis · from the 250-topic plan
The cost of quitting: the total-ownership math nobody runs before canceling
Quitting looks like the only plan that costs $0/month, and the ledger disagrees. The lines quitting actually carries: the regain line — the withdrawal trial's roughly-half-back-within-a-year average, with the comorbidity trajectories that regain drags behind it; the restart line — re-titration weeks at starter doses, fresh intake fees, and re-entry at whatever prices then exist (the come-back-anytime clauses promise the door, not today's rate); and the opportunity line — months of progress interest forfeited. Against that ledger, the cheaper-than-quitting menu is long: tier-payers switch to the audited $139 flat and save $1,300–$1,900/year; budget-capped patients step to the $119 semaglutide floor; maintenance-phase economics get a prescriber conversation; and HSA/FSA treatment shaves 20–35% off everything. When quitting is still right — pregnancy runway, medical necessity, genuine choice — the off-ramp file does it properly. The full math — below.
Quitting's real ledger
The regain line, evidence-priced: the dedicated withdrawal trial watched patients who stopped regain, on average, roughly half of lost weight within a year while continuers maintained — not a scare statistic, a base rate — and regain rarely travels alone: the blood pressure, glycemic, lipid, airway, and joint improvements that arrived with loss tend to reverse with it, each carrying its own downstream costs in care, medications, and quality of life. The restart line: resuming after a long gap means the ladder from the bottom — weeks at sub-therapeutic starter doses, the adaptation window re-run, intake fees re-paid, and pricing re-set to the future's menu, since today's audited floors are dated claims, not lifetime guarantees. The opportunity line: the months between quit and restart aren't neutral — they're the compounding period where maintenance would have banked the win. None of this makes continuing mandatory; it makes “quitting is free” a bookkeeping error.
The cheaper-than-quitting menu
Ordered by savings size. The tier escape: anyone quitting a $250–$299 maintenance month over cost should price the switch first — the audited $139 flat saves $1,332–$1,920/year for one overlap month and a records transfer, usually converting “can't afford it” into “couldn't afford that program.” The molecule step-down: where even $139 strains, the $119 semaglutide floor holds a full evidence file at $240/year less — and the maintenance-after-tirzepatide analysis covers that specific sequence honestly. The dosing conversation: maintenance-phase strategies — where your prescriber lands on dose and cadence for the long hold — are clinical territory this site prices but never prescribes; the honest note is that holds and clinician-directed adjustments exist as tools before the exit does, and dose-proof pricing means exploring them costs nothing extra. The microdose floor, labeled: the $110–$129 lanes as a knowing step-down with the evidence caveat attached — a budget tool that beats zero. The tax shave: HSA/FSA treatment on any lane, 20–35% effective, per the cash-pay file. The coverage re-run: January's formulary may have moved — the denial translator and the employer lane reopen yearly.
Two worked cases
Case one — the $275 quitter: tier-priced at $275/month, considering quitting to save $3,300/year. The menu: switch to $139 ($1,668/year) — savings $1,632 — and keep the maintained weight, the stable comorbidity lines, and the avoided restart. Quitting “saves” the remaining $1,668 only if the regain line, the eventual-restart line, and the health-trajectory line total less — a bet the withdrawal data prices badly. Case two — the genuine cap: budget hard-stops at $100. The honest menu: the $110 microdose floor (knowingly, with a prescriber), an HSA-funded $119 standard lane if any pre-tax room exists, a family-plan conversation per the household file — and if the answer is still quit, then quit properly: the off-ramp's taper logic, habit-floor reinforcement, and honest regain expectations, with the door explicitly kept open. The site's position, stated once: this page argues with the arithmetic of quitting, never with the right to. The $139 escape from tier pricing ↗
When quitting is right
The ledger flips for real reasons: the pregnancy runway (a bright line, planned properly); medical necessity per your prescriber; side effects that survived every tool in the ledger's protocol chapter; and the legitimate choice to stop, owed a plan rather than a lecture — the off-ramp file exists precisely because this site takes that choice seriously enough to engineer it.
FAQ
What happens financially if I quit GLP-1 therapy?
The $0/month is offset by evidence-priced lines: average regain of roughly half within a year with its comorbidity trail, restart costs (re-titration, fees, future pricing), and forfeited maintenance months — quitting is a ledger, not a savings.
What's cheaper than quitting over cost?
In order: escaping tier pricing to the $139 audited flat (saves $1,300–$1,900/year), the $119 semaglutide floor, prescriber-led maintenance strategies, the labeled microdose floor, HSA/FSA treatment, and the annual coverage re-run.
Is it bad to stop and restart later?
It's priced: re-titration from starter doses, re-run adaptation, new intake fees, and then-current pricing — the come-back clauses guarantee the door, not today's rate.
When is quitting the right call?
Pregnancy planning, medical necessity, protocol-resistant side effects, or genuine choice — done via the off-ramp file's taper logic and habit floor, door kept open.
Sources
- Withdrawal-trial regain data; maintenance-continuation evidence.
- Audited pricing dataset (switch and step-down math).
- Companion files: off-ramp, maintenance file, microdose evidence, household logistics.